Tuna salad recalled in US: Listeria alert hits 7 states; full list of affected regions
Grocery stores across seven US states have pulled tuna salad items off their shelves after fears of listeria contamination. The recall, announced by the US food and drug administration (FDA) on Monday, was linked to products supplied by Reser's Fine Foods.
The contamination was traced to breadcrumbs used in the tuna salads. No cases of illness have been reported so far.
The affected items include sandwiches, croissants, snack packs and salad trays sold in Jewel-Osco outlets in Illinois, Indiana and Iowa, and in Albertsons, Randalls and Tom Thumb stores in Arkansas, Louisiana, Oklahoma and Texas. All the products have specific sell-by dates between 16 and 19 July.
Customers have been advised to throw away or return recalled items for a full refund.
What is Listeria
Listeria is a bacteria that can cause severe illness, especially in pregnant people, the elderly, children and those with low immunity. The infection may lead to fever, nausea, diarrhoea or, in serious cases, miscarriage or stillbirth.
The FDA has also asked people to clean all surfaces that may have come into contact with the products, warning that listeria can survive in cold storage like refrigerators.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
US targets knockoff weight-loss drugs
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market—a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group—spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey—asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalise on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage but are no longer permitted to do so after Novo Nordisk and Eli Lilly boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalisations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health , one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments.
Mint
5 hours ago
- Mint
Vinay Prasad is a Bernie Sanders acolyte in MAHA drag
Meet Vinay Prasad, a young disciple of Bernie Sanders who ranks as one of the most powerful officials in the federal government. He determines whether patients get access to many life-saving medicines. Or not. Think of him as a one-man death panel. Dr. Prasad was named by Marty Makary, the Food and Drug Administration commissioner, as head of the agency's biologics division in May, and last month as its chief medical and scientific officer. More on why he was tapped to these posts later. But it isn't an exaggeration to say that Dr. Prasad wields more power than Anthony Fauci ever did at the National Institutes of Health. Like Dr. Fauci, Dr. Prasad thinks he knows what's best for people, and that it's government's job to make it happen. 'I favor a strong regulatory state," he proudly professes. And just as Dr. Fauci slowed experimental HIV treatments during the 1980s by rigidly adhering to strict trial protocols, Dr. Prasad is now scuttling potentially life-saving therapies. In recent weeks, the FDA has rejected three therapies for debilitating diseases that have shown promise in clinical trials. The agency has also forced off the market a gene therapy that can slow the degenerative loss of muscular function in young boys with certain genetic mutations. Behold America's strong and arbitrary regulatory state at work. If you read Dr. Prasad's paper—or follow his smash-mouth Substack and feeds—the FDA's recent actions are no surprise. Dr. Prasad has long criticized the FDA for approving too many treatments that, in his view, provide only marginal benefits. He's also lambasted President Trump's first-term 'right to try" law, which lets terminally ill patients try experimental drugs not yet approved by the FDA. 'It is crucial to question whether non-curative therapies . . . are worth it," Dr. Prasad wrote in a 2021 paper about an FDA-approved cell therapy for multiple myeloma. The therapy reduced disease progression or death by half in patients with advanced cancers who hadn't responded to already approved therapies. Impressive. But Dr. Prasad complained that the treatment was pricey (then $419,500 for a course) and may 'only delay inevitable progression" in some patients. In other words, sick patients should just give up and die. Got that? In 2016 he wrote an op-ed titled 'The case for rationing: Why we should limit public spending on cancer drugs." He exalted the United Kingdom's socialized health system for restricting access to new treatments until they demonstrate a high degree of efficacy in multiple trials and that their benefits—as determined by the government—exceed their costs. Such government rationing is why survival rates for hard-to-treat cancers are much lower in the U.K. than in America—and why British patients with the financial means cross the pond to receive innovative and often life-saving treatments. Tough luck to Brits of average means. Of course, Dr. Prasad insists he really has patients' best interests at heart. Why would terminally ill patients want to waste their precious remaining time on earth schlepping to hospitals for treatments that may not cure them when they could be preparing for their deaths? That's the gist of his 2022 paper, which estimated patients with advanced cancers spend 16 more hours a month accessing and receiving novel treatments than if they accepted hospice or home palliative care. 'Time is a valuable resource for people who have cancer," the paper noted. Yes, and that's why they want to continue living. He has also argued that 'genome-informed cancer medicine"—treatments targeted based on a patient's genes or tumor mutations—'is mostly hype," no matter that such treatments have produced most recent improvements in cancer survival. Take CAR T-Cell therapies that re-engineer a patient's immune cells to target proteins on tumor cells. Such therapies can cure aggressive cancers that not long ago carried a death sentence, though Dr. Prasad has hyped their side effects. He has done the same for Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy, which the agency this month forced off the market after two patients in the advanced stages of the disease died from apparent side effects. The deaths look to have been a pretext for Dr. Prasad to deep-six the drug, which he had previously criticized as too costly for its benefits. Most treatments carry rare, life-threatening side effects, but doctors and patients can weigh their risks against their benefits. Perhaps Dr. Prasad doesn't trust people to do so any more than Dr. Fauci did. Dr. Prasad found common cause with Dr. Makary and conservatives in opposing paternalistic Covid policies including vaccine mandates and school shutdowns. But his other positions are at odds with Dr. Makary's stated support for more flexible reviews of drugs that treat rare and deadly diseases and the MAHA ethos of patient empowerment. Dr. Makary in spring 2021 lambasted the FDA for using the 'eternal excuse of safety" to pause the Johnson & Johnson Covid vaccine after a rare blood-clotting side effect cropped up, mostly in middle-aged women. 'This is a life-saving medication," he then wrote. 'What ever happened to giving people the data and letting them make their own health decisions?"
Hindustan Times
6 hours ago
- Hindustan Times
Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag
Meet Vinay Prasad, a young disciple of Bernie Sanders who ranks as one of the most powerful officials in the federal government. He determines whether patients get access to many life-saving medicines. Or not. Think of him as a one-man death panel. Dr. Prasad was named by Marty Makary, the Food and Drug Administration commissioner, as head of the agency's biologics division in May, and last month as its chief medical and scientific officer. More on why he was tapped to these posts later. But it isn't an exaggeration to say that Dr. Prasad wields more power than Anthony Fauci ever did at the National Institutes of Health. Vinay Prasad. Like Dr. Fauci, Dr. Prasad thinks he knows what's best for people, and that it's government's job to make it happen. 'I favor a strong regulatory state,' he proudly professes. And just as Dr. Fauci slowed experimental HIV treatments during the 1980s by rigidly adhering to strict trial protocols, Dr. Prasad is now scuttling potentially life-saving therapies. In recent weeks, the FDA has rejected three therapies for debilitating diseases that have shown promise in clinical trials. The agency has also forced off the market a gene therapy that can slow the degenerative loss of muscular function in young boys with certain genetic mutations. Behold America's strong and arbitrary regulatory state at work. If you read Dr. Prasad's paper—or follow his smash-mouth Substack and feeds—the FDA's recent actions are no surprise. Dr. Prasad has long criticized the FDA for approving too many treatments that, in his view, provide only marginal benefits. He's also lambasted President Trump's first-term 'right to try' law, which lets terminally ill patients try experimental drugs not yet approved by the FDA. 'It is crucial to question whether non-curative therapies . . . are worth it,' Dr. Prasad wrote in a 2021 paper about an FDA-approved cell therapy for multiple myeloma. The therapy reduced disease progression or death by half in patients with advanced cancers who hadn't responded to already approved therapies. Impressive. But Dr. Prasad complained that the treatment was pricey (then $419,500 for a course) and may 'only delay inevitable progression' in some patients. In other words, sick patients should just give up and die. Got that? In 2016 he wrote an op-ed titled 'The case for rationing: Why we should limit public spending on cancer drugs.' He exalted the United Kingdom's socialized health system for restricting access to new treatments until they demonstrate a high degree of efficacy in multiple trials and that their benefits—as determined by the government—exceed their costs. Such government rationing is why survival rates for hard-to-treat cancers are much lower in the U.K. than in America—and why British patients with the financial means cross the pond to receive innovative and often life-saving treatments. Tough luck to Brits of average means. Of course, Dr. Prasad insists he really has patients' best interests at heart. Why would terminally ill patients want to waste their precious remaining time on earth schlepping to hospitals for treatments that may not cure them when they could be preparing for their deaths? That's the gist of his 2022 paper, which estimated patients with advanced cancers spend 16 more hours a month accessing and receiving novel treatments than if they accepted hospice or home palliative care. 'Time is a valuable resource for people who have cancer,' the paper noted. Yes, and that's why they want to continue living. He has also argued that 'genome-informed cancer medicine'—treatments targeted based on a patient's genes or tumor mutations—'is mostly hype,' no matter that such treatments have produced most recent improvements in cancer survival. Take CAR T-Cell therapies that re-engineer a patient's immune cells to target proteins on tumor cells. Such therapies can cure aggressive cancers that not long ago carried a death sentence, though Dr. Prasad has hyped their side effects. He has done the same for Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy, which the agency this month forced off the market after two patients in the advanced stages of the disease died from apparent side effects. The deaths look to have been a pretext for Dr. Prasad to deep-six the drug, which he had previously criticized as too costly for its benefits. Most treatments carry rare, life-threatening side effects, but doctors and patients can weigh their risks against their benefits. Perhaps Dr. Prasad doesn't trust people to do so any more than Dr. Fauci did. Dr. Prasad found common cause with Dr. Makary and conservatives in opposing paternalistic Covid policies including vaccine mandates and school shutdowns. But his other positions are at odds with Dr. Makary's stated support for more flexible reviews of drugs that treat rare and deadly diseases and the MAHA ethos of patient empowerment. Dr. Makary in spring 2021 lambasted the FDA for using the 'eternal excuse of safety' to pause the Johnson & Johnson Covid vaccine after a rare blood-clotting side effect cropped up, mostly in middle-aged women. 'This is a life-saving medication,' he then wrote. 'What ever happened to giving people the data and letting them make their own health decisions?'
